The human prion octarepeat fragment prevents and reverses the inhibitory action of copper in the P2X4 receptor without modifying the zinc action

J Neurochem. 2003 May;85(3):709-16. doi: 10.1046/j.1471-4159.2003.01705.x.

Abstract

Human prion protein fragments (PrP60-67 or PrP59-91) prevented and reversed the inhibition elicited by 5 micro m copper on the P2X4 receptor expressed in Xenopus laevis oocytes. A 60-s pre-application of 5 micro m copper caused a 69.2 +/- 2.6% inhibition of the 10 micro m adenosine triphosphate (ATP)-evoked currents, an effect that was prevented by mixing 5 micro m copper with 0.01-10 micro m of the PrP fragments 1-min prior to application. This interaction was selective, as PrP59-91 did not alter the facilitatory action of zinc. The EC50 of PrP60-67 and PrP59-91 for the reduction of the copper inhibition were 4.6 +/- 1 and 1.3 +/- 0.4 micro m, respectively. A synthetic PrP59-91 variant in which all four His were replaced by Ala was inactive. However, the replacement of Trp in each of the four putative copper-binding domains by Ala slightly decreased its potency. Furthermore, the application of 10 micro m PrP59-91 reversed the copper-evoked inhibition, restoring the ATP concentration curve to the same level as the non-inhibited state. Fragment 139-157 of betaA4 amyloid precursor protein also prevented the action of copper; its EC50 was 1.6 +/- 0.1 micro m; the metal chelator penicillamine was equipotent with PrP60-67, but carnosine was significantly less potent. Our findings highlight the role of PrP in copper homeostasis and hint at its possible role as a modulator of synapses regulated by this trace metal.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenosine Triphosphate / pharmacology
  • Amino Acid Substitution
  • Amyloid beta-Protein Precursor / pharmacology
  • Animals
  • Binding Sites / genetics
  • Chelating Agents / pharmacology
  • Copper / antagonists & inhibitors*
  • Copper / pharmacology
  • Dose-Response Relationship, Drug
  • Humans
  • Microinjections
  • Oocytes / drug effects
  • Oocytes / metabolism
  • Patch-Clamp Techniques
  • Peptide Fragments / pharmacology*
  • Prions* / pharmacology*
  • Purinergic P2 Receptor Antagonists*
  • Receptors, Purinergic P2 / metabolism
  • Receptors, Purinergic P2X4
  • Repetitive Sequences, Amino Acid / physiology*
  • Structure-Activity Relationship
  • Xenopus laevis
  • Zinc / pharmacology*

Substances

  • Amyloid beta-Protein Precursor
  • Chelating Agents
  • P2RX4 protein, human
  • Peptide Fragments
  • Prions
  • Purinergic P2 Receptor Antagonists
  • Receptors, Purinergic P2
  • Receptors, Purinergic P2X4
  • betaA4 amyloid precursor protein (139-157), human
  • prion protein (59-91)
  • prion protein (60-67)
  • Copper
  • Adenosine Triphosphate
  • Zinc